Skip to main content

Table 1 Characteristics of included patients

From: Monitoring patients with juvenile idiopathic arthritis using health-related quality of life

  Total cJADAS-71 < =1.5 or < =2.5a cJADAS-71 > 1.5 or > 2.5b
Patients, n (%) 68 35 33
Female, n (%) 47 (69) 24 (69) 23 (70)
JIA Subcategory, n (%)
Oligoarticular JIA persistent 27 (40) 12 (34) 15 (45)
Oligoarticular JIA extended 6 (9) 3 (9) 3 (9)
Polyarticular JIA RF- 15 (22) 9 (26) 6 (18)
Polyarticular JIA RF+ 5 (7) 1 (3) 4 (12)
Psoriatic Arthritis 7 (10) 6 (17) 1 (3)
Enthesitis Related Arthritis 5 (7) 2 (6) 3 (9)
Systemic JIA 1 (2) 1 (3) 0 (−)
Undifferentiated JIA 2 (3) 1 (3) 1 (3)
Age at visit, median (IQR), y 13.6 (10.5–16.4) 13.3 (11.0–15.6) 14.1 (9.0–16.9)
Age at disease onset, median (IQR), y 7.6 (3.1–12.1) 6.7 (3.0–11.2) 9.4 (3.4–13.6)
Disease duration, median (IQR), y 4.6 (1.5–7.7) 6.4 (2.7–8.4) 2.4 (1.2–6.3)
cJADAS-71, median (IQR) 1.8 (0.1–6.1) 0.1 (0.0–0.7) 6.5 (4.0–9.5)
Treatment at Visit
Biologic DMARD, n (%)
  Adalimumab 17 (25) 10 (29) 7 (21)
  Etanercept 8 (12) 4 (11) 4 (12)
  Golimumab 4 (6) 0 (−) 4 (12)
Synthetic DMARD, n (%)
  Methotrexate 30 (44) 17 (49) 13 (39)
  Other DMARD 5 (7) 3 (9) 2 (6)
No Biologic or Synthetic DMARD n (%) 24 (35) 12 (34) 12 (36)
  1. cJADAS-71: clinical juvenile arthritis disease activity score with 71 joint count; DMARD: disease modifying anti-rheumatic drug; IQR: interquartile range. aLow disease activity for oligoarticular or polyarticular JIA, respectively. b Moderate or high disease activity for oligoarticular or polyarticular JIA, respectively